News
RDHL
0.2657
-27.21%
-0.0993
Dow Drops 100 Points; Asana Shares Plummet
Benzinga · 2d ago
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
Gold Down 1%; Samsara Shares Spike Higher
Benzinga · 2d ago
BRIEF-Redhill Biopharma Prices $8.0 Million Underwritten Public Offering
Reuters · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2d ago
Why UiPath Shares Are Trading Higher By Around 8%; Here Are 24 Stocks Moving Premarket
Benzinga · 2d ago
RedHill Biopharma Prices 32-Million-Unit Underwritten Public Offering at $0.25 per American Depositary Share
RedHill Biopharma Prices 32-Million-Unit Underwritten Public Offering at $0.25 per American Depositary Share
MT Newswires · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 3d ago
BRIEF-Redhill Biopharma Announces Proposed Public Offering
Reuters · 3d ago
RedHill Biopharma Announces Proposed Public Offering, Size Not Disclosed
Benzinga · 3d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 5d ago
BRIEF-Redhill Biopharma Announces Q3/22 Results And Operational Highlights
Reuters · 5d ago
Redhill Biopharma Q3 EPS $(0.06) Down From $(0.05) YoY, Sales $17.60M Down From $21.61M YoY
Benzinga · 5d ago
-- Earnings Flash (RDHL) REDHILL BIOPHARMA Reports Q3 Revenue $17.6M
-- Earnings Flash (RDHL) REDHILL BIOPHARMA Reports Q3 Revenue $17.6M
MT Newswires · 5d ago
The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23%
Market forces rained on the parade of RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shareholders today, when the covering...
Simply Wall St. · 11/24 10:19
BRIEF-RedHill Biopharma Announces Positive New Data With Opaganib For Nuclear Radiation Injury
Reuters · 11/17 13:52
RedHill Biopharma Announces New Data With Opaganib For Nuclear Radiation Injury
Benzinga · 11/17 13:37
RedHill Biopharma set to lose key revenue source, could 'cease operations'
A Raleigh drugmaker that previously announced plans to cut its commercial workforce is now likely to lose its primary source of revenue in order to wipe out debt. It will likely need sources of capital to keep operations going.
American City Business Journals · 11/15 20:09
RedHill rises on plans to settle debt in exchange for rights to constipation drug Movantik
Seekingalpha · 11/14 16:22
More
Webull provides a variety of real-time RDHL stock news. You can receive the latest news about Redhill Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About RDHL
Redhill Biopharma Ltd is an Israel-based specialty biopharmaceutical company, principally focused on gastrointestinal (GI) and infectious diseases. The Company is focused on the commercialization in the United States (U.S.) of the GI-related products, Movantik (naloxegol),Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). A part form Company's pipeline consists of six therapeutic candidates RHB-204 dedicated to Nontuberculous mycobacterial (NTM) treatment, RHB-104 dedicated to Crohn's disease, RHB-102 antiemetic drug ondansetron, in development for multiple gastrointestinal indications, RHB-106 an oral capsule formulation for bowel preparation, Opaganib an inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities and RHB-107 inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.